Coherus BioSciences to Participate at Upcoming November Investor Conferences

November 02, 2023 | Last Trade: US$0.79 0.04 -4.25

REDWOOD CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences:

Truist Securities BioPharma Symposium In New York City on Wednesday, November 8, 2023, for 1x1 meetings only.
UBS Biopharma Conference in Miami on Thursday, November 9, 2023, a fireside chat presentation at 11:30 a.m. Eastern Time will be webcast.
6th Annual Evercore ISI HealthCONx Conference in Miami on November 28-30, 2023, a fireside chat presentation on November 30th at 12:30 p.m. Eastern Time will be webcast.

A live audio webcast and an archive of the presentations from UBS Biopharma and Evercore ISI HealthCONx conferences will be available on the investors’ page of the Coherus website at http://investors.coherus.com.

Coherus Contact Information:
Jami Taylor
VP, Investor Relations
IR@coherus.com

Stock Quote

Last Trade:	US$0.79
Daily Change:	-0.04 -4.25
Daily Volume:	2,609,786
Market Cap:	US$91.020M

May 12, 2025 Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update April 28, 2025 Coherus BioSciences Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025 March 25, 2025 Coherus BioSciences to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting March 10, 2025 Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update January 22, 2025 Coherus BioSciences Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 LOAD MORE NEWS

Featured Stock

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE